Pfizer picks up early-stage ADC candidate cleared for solid tumor trials

Just days af­ter clos­ing its Seagen ac­qui­si­tion, Pfiz­er has struck a deal to ex­pand its an­ti­body-drug con­ju­gate port­fo­lio even fur­ther.

Nona Bio­sciences, the part­ner­ship-dri­ven an­ti­body shop launched by Har­bour Bio­Med, says Pfiz­er is li­cens­ing glob­al de­vel­op­ment and com­mer­cial­iza­tion rights to its mesothe­lin-tar­get­ed ADC, HBM9033.

Pfiz­er will hand over up to $53 mil­lion in up­front and near-term pay­ments while promis­ing mile­stones that can reach $1.05 bil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.